ATyr Pharma Q2 Net Loss Narrows; Cuts Workforce By 60% To Advance Efzofitimod Into Phase 3

(RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD).

aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development for the treatment of ILD, including pulmonary sarcoidosis and systemic sclerosis (SSc)-related ILD (SSc-ILD), that can cause inflammation and progressive fibrosis, or scarring, of the lungs.

Second Quarter Results

For the second quarter of 2026, net loss attributable to aTyr Pharma narrowed to $10.31 million or $0.11 per share from $19.53 million or $0.22 per share in the prior year.

As of June 30, 2026, cash and cash equivalents totalled $58.9 million, including restricted cash and available-for-sale investments. aTyr Pharma anticipates that this cash position will be sufficient to fund the Company's current operations into late 2028.

Corporate Restructuring Highlights

The company is anticipating feedback from the U.S. Food and Drug Administration (FDA) on the protocol for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis, a major form of ILD.

According to the company, a workforce reduction of approximately 60% will align organisational resources to support advancing efzofitimod in ILD and to complete the Phase 2 EFZO-CONNECT study in SSc-ILD.

In addition, Jill Broadfoot, aTyr's Chief Financial Officer (CFO), will step down as of September 30, 2026, and transition to serve as a consultant to the company and Brandon Yaras, aTyr's Vice President of Finance, will be appointed as CFO as of October 1, 2026.

The company expects that this restructuring and additional cost-saving measures will reduce annualised operating expenses by approximately $13 million, beginning in the fourth quarter of 2026.

Upcoming Milestones

Feedback from the FDA on the protocol for its planned Phase 3 study of efzofitimod is expected by the end of August 2026.

Notably, the company said future development of efzofitimod in the planned Phase 3 study in pulmonary sarcoidosis will require additional financing through equity or debt offerings, grant funding, collaborations, strategic partnerships and/or licensing arrangements.

In the Phase 2 EFZO-CONNECT study of efzofitimod in patients with limited or diffuse SSc-ILD, enrollment is complete, and topline results are expected in the first quarter of 2027.

Stock Performance

ATYR has traded between $0.39 and $6.50 over the last year. The stock closed Friday's trade at $0.511, up 1.87%.

For more such biotechstock news visit rttnews.com.